High materiality10/10
Opus Genetics initiated with an Outperform at RBC Capital
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
bullish
What happened, with direct paths to the underlying reporting
RBC Capital initiated coverage on Opus Genetics (IRD) with an Outperform rating; target price $10 vs a $4.08 current price, implying substantial upside.
Target: $10
Posted price: $4.08
Analyst firm: RBC Capital
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.